Daiwa Securities upgraded Bristol-Myers from Neutral to Outperform
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 11/15/2024 | Peer Perform | Wolfe Research | |
| 11/13/2024 | Neutral → Outperform | Daiwa Securities | |
| 11/12/2024 | $73.00 | Market Perform → Outperform | Leerink Partners |
| 10/25/2024 | $75.00 → $55.00 | Buy → Neutral | Citigroup |
| 10/17/2024 | $56.00 | Mkt Perform | Bernstein |
| 7/29/2024 | $41.00 | Overweight → Equal Weight | Barclays |
| 3/11/2024 | Buy → Hold | Societe Generale | |
| 2/6/2024 | $77.00 → $54.00 | Buy → Neutral | Redburn Atlantic |
Opinion based on results from the Phase 3 CheckMate -8HW trial, in which the dual immunotherapy combination of Opdivo and Yervoy demonstrated statistically significant and clinically meaningful improvement in progression-free survival compared to investigator's choice of chemotherapy Bristol Myers Squibb (NYSE:BMY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended approval of Opdivo® (nivolumab) plus Yervoy® (ipilimumab) for the first-line treatment of adult patients with microsatellite instability–high (MSI-H) or mismatch repair deficient (dMMR) unresectable or metastatic colorectal cancer (mCRC). Of sign
Recommendation based on data from registrational TRIDENT-1 and CARE trials, which demonstrated robust responses and durable activity with repotrectinib in these patient populations If approved, repotrectinib has the potential to be a best-in-class treatment for patients with advanced ROS1-positive non-small cell lung cancer in the European Union Bristol Myers Squibb (NYSE:BMY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended approval for repotrectinib, a next-generation tyrosine kinase inhibitor (TKI), as a treatment for adult patients with ROS1-positive advanced non-small cell lung cancer (NSCLC) and f
Advancing investigation of [212Pb]VMT01 as a monotherapy and in combination with the anti-PD-1 antibody, nivolumab, in patients with previously treated metastatic melanoma, based on preliminary results presented at the 21st International Congress of the Society of Melanoma Research in OctoberPresenting initial results from the company-sponsored Phase 1/2a study of [212Pb]VMT-α-NET in patients with RPT-naïve neuroendocrine tumors at the upcoming 2024 North American Neuroendocrine Tumor Society Symposium in NovemberShipping of investigational product started in October from a second manufacturing facility in Somerset, New Jersey; additional facility expansion activities ongoingOn track to adva
Guggenheim Partners initiated coverage on Alumis Inc. (NASDAQ:ALMS), a clinical-stage biopharmaceutical company developing oral therapies for immune-mediated diseases. The investment thesis centers around a positive view of its lead asset ESK-001, a next-gen TYK2 inhibitor currently in development for plaque psoriasis and systemic lupus erythematosus (SLE). The company’s management expects to initiate a Phase 3 trial for plaque psoriasis in the second half of 2024, and data from the SLE study are expected in 2026. The analyst writes that favorable safety (with no risk of JAK class black box warning) and potential BIC efficacy make ESK-001 a potentially competitive alternative to ava
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. Goldman Sachs cut the price target for SunPower Corporation (NASDAQ:SPWR) from $2 to $0.5. Goldman Sachs analyst Brian Lee maintained a Sell rating. SunPower shares gained 5.4% to close at $0.7158 on Monday. See how other analysts view this stock. Piper Sandler increased the price target for Cathay General Bancorp (NASDAQ:CATY) from $32 to $36. Piper Sandler analyst Matthew Clark maintained an Underweight rating. Cathay General Bancorp shares gained 2.4% to close at $43.02 on Monday. See how other
Deutsche Bank analyst James Shin maintains Bristol-Myers Squibb (NYSE:BMY) with a Hold and lowers the price target from $53 to $45.
4 - BRISTOL MYERS SQUIBB CO (0000014272) (Issuer)
4 - BRISTOL MYERS SQUIBB CO (0000014272) (Issuer)
4 - BRISTOL MYERS SQUIBB CO (0000014272) (Issuer)
Concurrently, the Company accepted the resignations of Dr. Colin Goddard and Mr. Joacim Borg OS Therapies (NYSE-A: OSTX) ("OS Therapies" or "the Company"), a clinical-stage immunotherapy and Antibody Drug Conjugate biopharmaceutical company, today announced the appointments of Avril McKean Dieser, MA, JD and Olivier R. Jarry, MS, MBA as independent members of the Company's Board of Directors. Collectively, Ms. McKean Dieser and Mr. Jarry bring over 50 years of biopharmaceutical executive decision-making experience to the Company, with a specific focus in commercializing biologic products. "OS Therapies is thrilled to welcome Ms. McKean Dieser and Mr. Jarry to our Board of Directors," sa
Bristol Myers Squibb (NYSE:BMY) today announced that its Board of Directors has elected independent director Michael R. McMullen to the Board, effective July 1, 2024. Mr. McMullen will serve as a member of the Audit Committee of the Board of Directors. "We are pleased to welcome Mr. Michael McMullen to our Board of Directors," said Christopher Boerner, Ph.D., board chair and chief executive officer, Bristol Myers Squibb. "Mike's extensive experience in managing large businesses and global operations, combined with his proven track record of delivering excellent shareholder returns, will prove valuable as we continue to strengthen the company's long-term growth profile, progress our pipeli
Tapestry, Inc. (NYSE:TPR), a house of iconic accessories and lifestyle brands consisting of Coach, Kate Spade, and Stuart Weitzman, today announced that Kevin Hourican, President and Chief Executive Officer of Sysco Corporation (NYSE:SYY), and David Elkins, Executive Vice President and Chief Financial Officer of Bristol Myers Squibb (NYSE:BMY), have been appointed to the Company's Board of Directors. The appointments of Mr. Hourican and Mr. Elkins to the Board bring the membership to eleven, including ten independent directors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240229220934/en/Kevin Hourican (Photo: Business Wire) J
10-Q - BRISTOL MYERS SQUIBB CO (0000014272) (Filer)
8-K - BRISTOL MYERS SQUIBB CO (0000014272) (Filer)
10-Q - BRISTOL MYERS SQUIBB CO (0000014272) (Filer)
Performance Reflects Continued Focus on Near-Term Execution and Building a Foundation for Long-Term Sustainable Growth Third Quarter Revenues were $11.9 Billion, increasing 8% (+10% Adjusting for Foreign Exchange) Growth Portfolio Revenues were $5.8 Billion, increasing 18% (+20% Adjusting for Foreign Exchange) GAAP EPS was $0.60 and Non-GAAP EPS was $1.80; Includes Net Impact of $(0.09) Per Share for GAAP EPS and Non-GAAP EPS Due to Acquired IPRD Charges and Licensing Income Achieved U.S. Approval of Cobenfy, the First New Pharmacological Approach to Treat Schizophrenia in Decades Raising 2024 Revenue Guidance to Approximately +5% (+6% Adjusting for Foreign Exchange), Non-GAAP EPS
Bristol Myers Squibb (NYSE:BMY) will announce results for the third quarter of 2024 on Thursday, October 31, 2024. Company executives will review financial results and address inquiries from investors and analysts during a conference call beginning at 8:00 a.m. ET on the same date. Investors and the general public are invited to listen to a live webcast of the call at http://investor.bms.com. Investors and the public can register for the live conference call here. Those unable to register can access the live conference call by dialing in the U.S. toll free 1-833-816-1116 or international +1 412-317-0705. Materials related to the call will be available at http://investor.bms.com prior to th
Bristol Myers Squibb (NYSE:BMY) today announced that its Board of Directors has declared a quarterly dividend of sixty cents ($0.60) per share on the $0.10 par value common stock of the company. The dividend is payable on November 1, 2024, to stockholders of record at the close of business on October 4, 2024. In addition, the Board of Directors has declared a quarterly dividend of fifty cents ($0.50) per share on the company's $2.00 convertible preferred stock, payable on December 2, 2024, to stockholders of record at the close of business on November 5, 2024. About Bristol Myers Squibb Company Bristol Myers Squibb is a global biopharmaceutical company whose mission is to discover, devel
Wolfe Research initiated coverage of Bristol-Myers with a rating of Peer Perform
Daiwa Securities upgraded Bristol-Myers from Neutral to Outperform
Leerink Partners upgraded Bristol-Myers from Market Perform to Outperform and set a new price target of $73.00
4 - BRISTOL MYERS SQUIBB CO (0000014272) (Issuer)
4 - BRISTOL MYERS SQUIBB CO (0000014272) (Issuer)
4 - BRISTOL MYERS SQUIBB CO (0000014272) (Issuer)
For Immediate Release: September 26, 2024 Today, the U.S. Food and Drug Administration approved Cobenfy (xanomeline and trospium chloride) capsules for oral use for the treatment of schizophrenia in adults. It is the first antipsychotic drug approved to treat schizophrenia that targets cholinergic receptors as opposed to dopamine receptors, which has long been the standard of care. “Schizophrenia is a leading
For Immediate Release: June 14, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency: Today, the FDA issued a proposed exemption for certain cottage cheese products from the requirements of the Food Traceability Rule. The proposal would exempt Grade “A” cottage cheese that appears on the Interstate Milk Shippers List from the requirements of the r
For Immediate Release: March 08, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency: Today, the FDA announced proposed new regulations to provide animal drug sponsors with predictable requirements for the labeling of prescription and over-the-counter new animal drugs, as well as new animal drugs for use in animal feeds. The proposed content and
SC 13G/A - BRISTOL MYERS SQUIBB CO (0000014272) (Subject)
SC 13G/A - BRISTOL MYERS SQUIBB CO (0000014272) (Subject)
SC 13G/A - BRISTOL MYERS SQUIBB CO (0000014272) (Subject)